首頁 > 市場調查報告書 > 醫療設備

e保健

市場調查報告書

商品編碼

2069202

基於數位生物標記的認知健康市場預測（至2034年）：按組件、數據模式、應用、最終用戶和地區分類的全球分析

Digital Biomarker-Based Cognitive Health Market Forecasts to 2034 - Global Analysis By Component (Hardware, Software and Services), Data Modality, Application, End User and By Geography

出版日期: 2026年06月11日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，全球基於數位生物標記的認知健康市場預計將在 2026 年達到 103 億美元，並在預測期內以 10.9% 的複合年成長率成長，到 2034 年達到 236 億美元。

基於數位生物標記的認知健康是指利用透過數位設備、感測器和軟體應用程式收集的可測量數據，對認知功能進行評估、監測和管理。這些數位生物標記能夠捕捉反映記憶力、注意力、推理能力和其他認知能力變化的行為、生理和互動指標。透過實現持續客觀的評估，這種方法有助於早期發現認知衰退、提供個人化介入措施以及進行數據驅動的醫療決策。此外，它還能透過即時洞察、遠端監測功能和提高臨床評估的準確性，增強認知健康管理。

神經系統疾病負擔日益加重

隨著阿茲海默症、帕金森氏症和其他神經退化性疾病在全球範圍內的發病率持續上升，基於數位生物標記的認知功能管理解決方案正受到廣泛關注。醫療保健系統面臨越來越大的壓力，需要在認知衰退的早期階段識別出患者，以便儘早進行干預，從而達到最佳療效。製藥公司也越來越依賴數位生物標記來驗證臨床試驗中的治療效果。已開發國家人口老化使得遠距認知監測能力的需求持續成長。這些因素共同推動了數位生物標記平台在臨床和研究領域的應用。

與監管檢驗相關的挑戰

數位生物標記技術的廣泛應用面臨法規核准和臨床有效性檢驗的重大挑戰。例如，FDA等監管機構要求提供大量證據，證明數位生物標記與既定的臨床終點之間存在相關性。認知障礙的多樣性也增加了製定標準化生物標記方案的難度。持續神經系統監測相關的資料隱私問題進一步加重了合規負擔。醫療機構對於將未經驗證的數位指標納入臨床決策流程仍然持謹慎態度。這些檢驗和監管方面的障礙正在延緩商業化檢驗。

人工智慧驅動的預測分析

人工智慧 (AI) 和機器學習正為基於數位生物標記的認知健康解決方案帶來創新機會。先進的演算法能夠識別多模態資料中細微的模式，這些模式預示著認知衰退的臨床可偵測徵兆。預測模型能夠實現個人化的風險分層和預防性介入策略。與電子健康記錄的整合支持在人群層面監測認知健康。製藥公司正日益尋求採用人工智慧驅動的數位終點來加速藥物研發進程。這些技術進步正將數位生物標記定位為精準神經科學的重要基礎。

資料互通性限制

由於資料格式不相容和平台架構各異，數位生物標記生態系統面臨嚴重的片段化問題。各感測器製造商採用的非標準協定使得跨裝置的資料聚合變得複雜。缺乏通用的資料交換標準限制了多中心臨床試驗的擴充性。醫療機構難以將分散的數位生物標記數據流整合到統一的臨床儀表板中。對供應商鎖定的擔憂導致醫療機構在採用特定技術平台時猶豫不決。這些互通性挑戰阻礙了數位生物標記解決方案的廣泛應用。

新型冠狀病毒（COVID-19）的影響：

新冠疫情初期擾亂了臨床研究的進行，並延緩了多個治療領域數位生物標記的檢驗研究。然而，隨著醫療系統尋求替代面對面認知評估的方法，這場危機迅速加速了遠端患者監護的普及。疫情後，人們對遠端醫療基礎設施的關注，催生了對數位生物標記平台的持續需求。此外，對新冠感染後長期認知障礙的認知，也進一步刺激了數位認知監測技術的研究投入。

在預測期內，軟體領域預計將佔據最大的市場佔有率。

在預測期內，軟體領域預計將佔據最大的市場佔有率。這是因為演算法平台在處理和解讀複雜的多模態生物標記數據方面發揮核心作用。先進的分析引擎、機器學習模型和基於雲端的資料管理系統構成了數位生物標記解決方案的核心智慧財產權。軟體平台能夠實現即時訊號處理、模式識別和預測建模，將原始感測器數據轉化為臨床適用的見解。由軟體即服務 (SaaS) 模式驅動的持續收入模式正在支撐市場的持續成長。

在預測期內，認知功能資料區段預計將呈現最高的複合年成長率。

在預測期內，認知功能資料區段預計將呈現最高的成長率，這主要得益於對執行功能、記憶力和注意力等客觀量化指標日益成長的需求。透過智慧型手機和平板電腦進行的數位化認知功能評估，為傳統的神經心理學測驗提供了高度擴充性的替代方案。藥廠要求在失智症治療臨床試驗的監管申報中使用標準化的認知功能終點指標。將遊戲化的認知任務與被動監控結合，可以建構全面的認知功能概況。學術研究機構正積極進行檢驗研究，以確立數位化認知功能檢測法作為公認的臨床終點指標。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療基礎設施和大量的研發投入。美國憑藉其龐大的臨床試驗網路和FDA的數位健康指導框架（該框架有助於生物標記的檢驗）在該領域處於領先地位。領先的科技公司和醫療機構正在合作進行大規模的數位生物標記研究舉措。遠端患者監護的優惠報銷政策正在推動其商業性化應用。大型製藥企業的存在也推動了藥物研發項目中對數位終點的需求。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於數位醫療基礎設施的快速發展和老年人口的不斷成長。中國和日本是重要的成長機會所在，這得益於兩國政府大力支持智慧醫療和居家養老技術的措施。韓國先進的家用電子電器系統正在推動穿戴式健康監測感測器的應用。印度快速發展的製藥業正日益廣泛地在臨床研究中採用數位化終點。區域內的科技新創公司正獲得創業投資資金籌措，用於開發本地化的數位生物標記平台。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域細分
- 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第10章戰略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第11章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第12章：公司簡介

Apple Inc.
Alphabet Inc.[Google]
Samsung Electronics Co. Ltd.
Microsoft Corporation
IBM Corporation
Medtronic plc
Philips Healthcare
GE HealthCare Technologies Inc.
Empatica Inc.
Biofourmis Inc.
Neurotrack Technologies Inc.
Linus Health Inc.
Altoida Inc.
Cogstate Ltd.
Biogen Inc.

簡介目錄圖表

Product Code: SMRC37219

According to Stratistics MRC, the Global Digital Biomarker-Based Cognitive Health Market is accounted for $10.3 billion in 2026 and is expected to reach $23.6 billion by 2034 growing at a CAGR of 10.9% during the forecast period. Digital Biomarker-Based Cognitive Health refers to the assessment, monitoring, and management of cognitive function using measurable data collected through digital devices, sensors, and software applications. These digital biomarkers capture behavioral, physiological, and interaction-based indicators that reflect changes in memory, attention, reasoning, and other cognitive abilities. By enabling continuous and objective evaluation, this approach supports early detection of cognitive decline, personalized interventions, and data-driven healthcare decisions. It enhances cognitive health management through real-time insights, remote monitoring capabilities, and improved clinical assessment accuracy.

Market Dynamics:

Driver:

Rising neurological disease burden

Digital biomarker-based cognitive health solutions are gaining substantial traction as the global prevalence of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions continues to escalate. Healthcare systems face mounting pressure to identify cognitive decline at earlier stages when interventions remain most effective. Pharmaceutical companies increasingly rely on digital biomarkers to demonstrate treatment efficacy in clinical trials. The aging demographic across developed economies creates sustained demand for remote cognitive monitoring capabilities. These factors collectively accelerate the adoption of digital biomarker platforms across clinical and research settings.

Restraint:

Regulatory validation challenges

The widespread deployment of digital biomarker technologies faces significant hurdles related to regulatory approval and clinical validation. Regulatory bodies such as the FDA require extensive evidence demonstrating that digital biomarkers correlate with established clinical endpoints. The heterogeneity of cognitive disorders complicates the development of standardized biomarker protocols. Data privacy concerns surrounding continuous neurological monitoring create additional compliance burdens. Healthcare providers remain cautious about integrating unvalidated digital measures into clinical decision-making workflows. These validation and regulatory barriers slow commercialization timelines.

Opportunity:

AI-driven predictive analytics

Artificial intelligence and machine learning present transformative opportunities for digital biomarker-based cognitive health solutions. Advanced algorithms can identify subtle patterns in multimodal data that precede clinically detectable cognitive decline. Predictive models enable personalized risk stratification and proactive intervention strategies. Integration with electronic health records supports population-level cognitive health surveillance. Pharmaceutical sponsors increasingly seek AI-enhanced digital endpoints to accelerate drug development timelines. These technological advances position digital biomarkers as essential infrastructure for precision neurology.

Threat:

Data interoperability limitations

The digital biomarker ecosystem faces persistent fragmentation due to incompatible data formats and proprietary platform architectures. Different sensor manufacturers employ non-standardized protocols that complicate data aggregation across devices. The absence of universal data exchange standards limits the scalability of multi-site clinical studies. Healthcare institutions struggle to integrate disparate digital biomarker streams into unified clinical dashboards. Vendor lock-in concerns deter healthcare organizations from committing to specific technology platforms. These interoperability challenges constrain the broader adoption of digital biomarker solutions.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted clinical research operations and delayed digital biomarker validation studies across multiple therapeutic areas. However, the crisis rapidly accelerated remote patient monitoring adoption as healthcare systems sought alternatives to in-person cognitive assessments. Post-pandemic, the sustained emphasis on decentralized clinical trials and telehealth infrastructure has created permanent demand for digital biomarker platforms. The recognition of long-term cognitive sequelae associated with COVID-19 infection has further intensified research investment in digital cognitive monitoring technologies.

The software segment is expected to be the largest during the forecast period

The software segment is expected to account for the largest market share during the forecast period, due to the central role of algorithmic platforms in processing and interpreting complex multimodal biomarker data. Advanced analytics engines, machine learning models, and cloud-based data management systems constitute the core intellectual property of digital biomarker solutions. Software platforms enable real-time signal processing, pattern recognition, and predictive modeling that transform raw sensor data into clinically actionable insights. The recurring revenue model of software-as-a-service deployments supports sustained market expansion.

The cognitive performance data segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cognitive performance data segment is predicted to witness the highest growth rate, driven by increasing demand for objective, quantifiable measures of executive function, memory, and attention. Digital cognitive assessments administered through smartphones and tablets offer scalable alternatives to traditional neuropsychological testing. Pharmaceutical sponsors require standardized cognitive endpoints for regulatory submissions in dementia drug trials. The integration of gamified cognitive tasks with passive monitoring creates comprehensive cognitive profiles. Academic research institutions drive validation studies that establish digital cognitive measures as accepted clinical endpoints.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to advanced healthcare infrastructure and substantial research investment. The United States leads with extensive clinical trial networks and FDA digital health guidance frameworks that facilitate biomarker validation. Major technology companies and healthcare institutions collaborate on large-scale digital biomarker research initiatives. Favorable reimbursement policies for remote patient monitoring support commercial adoption. The presence of leading pharmaceutical sponsors drives demand for digital endpoints in drug development programs.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid digital health infrastructure development and expanding elderly populations. China and Japan represent major growth opportunities with government initiatives supporting smart healthcare and aging-in-place technologies. South Korea's advanced consumer electronics ecosystem facilitates wearable sensor adoption for health monitoring. India's growing pharmaceutical sector increasingly incorporates digital endpoints in clinical research. Regional technology startups receive venture capital funding to develop localized digital biomarker platforms.

Key players in the market

Some of the key players in Digital Biomarker-Based Cognitive Health Market include Apple Inc., Alphabet Inc. [Google], Samsung Electronics Co. Ltd., Microsoft Corporation, IBM Corporation, Medtronic plc, Philips Healthcare, GE HealthCare Technologies Inc., Empatica Inc., Biofourmis Inc., Neurotrack Technologies Inc., Linus Health Inc., Altoida Inc., Cogstate Ltd. and Biogen Inc.

Key Developments:

In May 2026, Apple Inc. launched an advanced cognitive health monitoring framework integrating Apple Watch sensors with on-device machine learning for early detection of mild cognitive impairment patterns.

In April 2026, Medtronic plc partnered with a leading academic medical center to validate digital biomarker endpoints for Parkinson's disease progression using continuous wearable sensor data collection.

In March 2026, Linus Health Inc. secured FDA clearance for its AI-powered digital cognitive assessment platform, enabling remote screening and longitudinal monitoring of brain health metrics.

Components Covered:

Hardware
Software
Services

Data Modalities Covered:

Physiological Signals
Behavioral Signals
Cognitive Performance Data
Environmental Contextual Data

Applications Covered:

Early Detection & Screening
Disease Monitoring & Progression Tracking
Clinical Trial Endpoint Support
Personalized Brain Health Management
Remote Patient Monitoring

End Users Covered:

Pharmaceutical & Biotech Companies
Healthcare Providers
Academic & Research Institutes
Payers & Insurance Companies
Consumers & Caregivers

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Digital Biomarker-Based Cognitive Health Market, By Component

5.1 Hardware
5.2 Software
5.3 Services

6 Global Digital Biomarker-Based Cognitive Health Market, By Data Modality

6.1 Physiological Signals
6.2 Behavioral Signals
6.3 Cognitive Performance Data
6.4 Environmental Contextual Data

7 Global Digital Biomarker-Based Cognitive Health Market, By Application

7.1 Early Detection & Screening
7.2 Disease Monitoring & Progression Tracking
7.3 Clinical Trial Endpoint Support
7.4 Personalized Brain Health Management
7.5 Remote Patient Monitoring

8 Global Digital Biomarker-Based Cognitive Health Market, By End User

8.1 Pharmaceutical & Biotech Companies
8.2 Healthcare Providers
8.3 Academic & Research Institutes
8.4 Payers & Insurance Companies
8.5 Consumers & Caregivers

9 Global Digital Biomarker-Based Cognitive Health Market, By Geography

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 United Kingdom
- 9.2.2 Germany
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Netherlands
- 9.2.7 Belgium
- 9.2.8 Sweden
- 9.2.9 Switzerland
- 9.2.10 Poland
- 9.2.11 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 South Korea
- 9.3.5 Australia
- 9.3.6 Indonesia
- 9.3.7 Thailand
- 9.3.8 Malaysia
- 9.3.9 Singapore
- 9.3.10 Vietnam
- 9.3.11 Rest of Asia Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Colombia
- 9.4.4 Chile
- 9.4.5 Peru
- 9.4.6 Rest of South America
9.5 Rest of the World (RoW)
- 9.5.1 Middle East
  - 9.5.1.1 Saudi Arabia
  - 9.5.1.2 United Arab Emirates
  - 9.5.1.3 Qatar
  - 9.5.1.4 Israel
  - 9.5.1.5 Rest of Middle East
- 9.5.2 Africa
  - 9.5.2.1 South Africa
  - 9.5.2.2 Egypt
  - 9.5.2.3 Morocco
  - 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives

12 Company Profiles

12.1 Apple Inc.
12.2 Alphabet Inc. [Google]
12.3 Samsung Electronics Co. Ltd.
12.4 Microsoft Corporation
12.5 IBM Corporation
12.6 Medtronic plc
12.7 Philips Healthcare
12.8 GE HealthCare Technologies Inc.
12.9 Empatica Inc.
12.10 Biofourmis Inc.
12.11 Neurotrack Technologies Inc.
12.12 Linus Health Inc.
12.13 Altoida Inc.
12.14 Cogstate Ltd.
12.15 Biogen Inc.

簡介目錄圖表

List of Tables

Table 1 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Component (2023-2034) ($MN)
Table 3 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Hardware (2023-2034) ($MN)
Table 4 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Software (2023-2034) ($MN)
Table 5 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Services (2023-2034) ($MN)
Table 6 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Data Modality (2023-2034) ($MN)
Table 7 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Physiological Signals (2023-2034) ($MN)
Table 8 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Behavioral Signals (2023-2034) ($MN)
Table 9 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Cognitive Performance Data (2023-2034) ($MN)
Table 10 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Environmental Contextual Data (2023-2034) ($MN)
Table 11 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Application (2023-2034) ($MN)
Table 12 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Early Detection & Screening (2023-2034) ($MN)
Table 13 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Disease Monitoring & Progression Tracking (2023-2034) ($MN)
Table 14 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Clinical Trial Endpoint Support (2023-2034) ($MN)
Table 15 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Personalized Brain Health Management (2023-2034) ($MN)
Table 16 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Remote Patient Monitoring (2023-2034) ($MN)
Table 17 Global Digital Biomarker-Based Cognitive Health Market Outlook, By End User (2023-2034) ($MN)
Table 18 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Pharmaceutical & Biotech Companies (2023-2034) ($MN)
Table 19 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Healthcare Providers (2023-2034) ($MN)
Table 20 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
Table 21 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Payers & Insurance Companies (2023-2034) ($MN)
Table 22 Global Digital Biomarker-Based Cognitive Health Market Outlook, By Consumers & Caregivers (2023-2034) ($MN)